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Abstract
The conjugation/de-conjugation of Small Ubiquitin-like Modifier (SUMO) has been shown to be associated with a diverse
set of physiologic/pathologic conditions. The clinical significance and ostensible therapeutic utility offered via the selective
control of the global SUMOylation process has become readily apparent in ischemic pathophysiology. Herein, we
describe the development of a novel quantitative high-throughput screening (qHTS) system designed to identify small
molecules capable of increasing SUMOylation via the regulation/inhibition of members of the microRNA (miRNA)-182
family. This assay employs a SHSY5Y human neuroblastoma cell line stably transfected with a dual firefly-Renilla luciferase
reporter system for identification of specific inhibitors of either miR-182 or miR-183. In this study, we have identified
small molecules capable of inducing increased global conjugation of SUMO in both SHSY5Y cells and rat E18-derived
primary cortical neurons. The protective effects of a number of the identified compounds were confirmed via an in vitro
ischemic model (oxygen/glucose deprivation). Of note, this assay can be easily repurposed to allow high-throughput
analyses of the potential drugability of other relevant miRNA(s) in ischemic pathobiology.
Keywords
High-throughput assay development, miRNA, neuroprotection, SUMO conjugation, translational research
Received 14 April 2015; Revised 5 August 2015; Accepted 27 August 2015
Introduction
Stroke is one of the most common causes of death and
disability worldwide. Due to an aging population, the
burden will markedly increase in the coming decades
and will be particularly pronounced in developing coun-
tries.1 Of strokes that occur in theUnited States, 87%are
ischemic, 10% are intracerebral hemorrhagic strokes,
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whereas 3% are subarachnoid hemorrhages.1 Based on
this distribution, the majority of research eﬀorts are
directed towards the development of interventions/
therapeutics capable of targeting the variety of patho-
physiological alterations that occur in ischemic stroke.
The continuing failure of clinical trials targeting
single mechanisms of neuroprotection in ischemic
stroke supports the view of ischemic brain damage as
a highly complex multifactorial process, that appears to
involve the interplay of many non-dominant eﬀectors.
In order to confront the enormous biocomplexity of
such network dynamics, it is prudent to focus on plur-
ifunctional targets that aﬀect multiple mechanisms gov-
erning homeostasis in states of both natural and
acquired tolerance to brain ischemia.
One such candidate that is capable of meeting the
aforementioned criteria is that of global SUMOylation.
SUMOylation is a form of post-translation modiﬁcation
that operates in states of tolerance and acts to preserve
homeostasis under stress via amyriad of beneﬁcial eﬀects
in the ischemic network.2 Brieﬂy, SUMO, like ubiquitin,
is synthesized as an inactive precursor and is processedby
SUMO-speciﬁc proteases to yield its mature form.3 A
single heterodimeric E1 enzyme, SAE1/SAE2, serves to
initiate conjugation by adenylating SUMO leading to the
formation of a covalent thioester E1-SUMO intermedi-
ate.3 SUMO is then transferred to the catalytic cysteine
of the sole E2 conjugase, Ubc9, which alone or in concert
with a target speciﬁc E3-ligase catalyses the formation of
an isopeptide linkage between the C-terminal glycine
residue of SUMO and the epsilon amino group of the
substrate lysine residue.3 SUMOconjugation is balanced
via the deconjugative actions of the various SUMO-spe-
ciﬁc proteases (SENPs).3,4 There are three systemically
distributed SUMO paralogs in mammals: SUMO-2 and
SUMO-3, which are 97% identical and cannot be distin-
guished by speciﬁc antibodies, and SUMO-1 which
shares only 50% homology with the other paralogs
and therefore has distinct immunoreactivity.3
SUMOylation has been documented to play a role in
numerous processes throughout the cell, including
signal transduction, gene expression, chromatin
remodeling, and protein translocation.3,5
Of particular interest in the context of ischemic
pathobiology were the changes (10–30 fold increases)
in global SUMOylation levels that have been reported
to occur during hibernation torpor in 13-lined ground
squirrels (Ictidomys tridecemlineatus)6 which are one of
the most resistant mammals to brain hypoperfusion.7
During torpor, these animals signiﬁcantly reduce their
brain blood ﬂow levels to roughly 10% of their base-
line, yet upon arousal show no evidence of cellular
damage and/or functional deﬁcits despite prolonged
exposure to perfusion levels characteristic of the ‘‘ische-
mic core’’.7,8 Further, in vitro work conducted in both
immortalized cell lines and primary cortical neuronal
cultures exposed to periods of oxygen and glucose
deprivation (OGD) conﬁrmed that increases in global
SUMOylation are in fact cytoprotective.9 We went on
to show that transgenic mice that overexpress Ubc9 do
in fact increase global SUMOylation levels and confer a
corresponding level of resistance to brain ischemia.10,11
In so doing, we established that the level of global
SUMOylation is directly proportional to the level of
cytoprotection in preclinical models of stroke.10
Additional work has since focused on elucidating the
molecular mechanisms that control the levels of global
SUMOylation. The goal of this eﬀort is to develop
methods capable of boosting global SUMOylation to
those levels seen in hibernating animals and to test
whether comparable cytoprotection can be reproduced
in stroke models. To this end, we have recently identiﬁed
a series of microRNAs serving as regulators of both
global SUMOylation and global post-translational
modiﬁcation by other ubiquitin-like modiﬁers (ULMs)
including NEDD8, ISG15, UFM1 and FUB1 (all of
which were signiﬁcantly increased in the brains of hiber-
nating ground squirrels during torpor).12 This report
was the ﬁrst to link the natural tolerance to brain ische-
mia, witnessed in hibernators, to multimodal regulation
by miRNAs. Analyses established that the miR-200
family (miR-200 a,b,c/miR-141/miR-429) and the
miR-182 family (miR-182/miR-183/miR-96) were con-
sistently depressed in the brain during the torpor phase
as compared to active animals.12 We showed that the
inhibition of the miR-200 family and/or miR-182 family
in SHSY5Y cells increased global protein conjugation
by the abovementioned ULMs, and in so doing made
these cells more resistant to OGD-induced cell death.12
Collectively, such evidence suggests that augmentation
of global SUMOylation may potentially be harnessed
and exploited for the protection of vulnerable ischemic
tissue through the manipulation of miRNA.
Herein we describe the development of a novel qHTS
assay designed to uncover small molecules that increase
global SUMOylation via inhibition of the miR-182
family. The validity of the assay was conﬁrmed by
immunoblotting. Of note, a select number of compounds
were capable of inducing protection duringOGD in both
SYSH5Y cells and E18 primary cortical neurons thereby
conﬁrming the functional utility of this assay.
Materials and methods
Generation of dual-luciferase miRNA target
expression constructs
The pmirGLO (Promega (Madison, WI, USA)) and the
psiCHECK-1 (Promega) vectors were designed to
quantitatively evaluate miRNA activity via the
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insertion of speciﬁc target sites into the 30 untranslated
region (UTR) of the ﬁreﬂy (pmirGLO vector) or
Renilla (psiCHECK-1) luciferase gene mRNA.
Starting from these two vectors, we built a dual repor-
ter construct with the miR-182 (or miR-183) target
sequence (Figure 1 and Supplementary Figure 1), so
that the presence of mature miR-182 or miR-183
would lead to a decrease in luciferase (both ﬁreﬂy and
Renilla) signal, enabling the detection of putative miR-
182 (or miR-183) levels. Post-construction, we exam-
ined whether these constructs would work as had
been predicted. We transfected SHSY5Y cells transi-
ently with these constructs along with either negative
control miRNA or miR-182 (or miR-183) mimics
(miRIDIAN micro RNA Negative control or Mimics,
Thermo Fisher Scientiﬁc (Waltham, MA, USA)) and
measured luciferase activities. As shown in
Supplementary Figure 2a, increased miR-182 (or -
183) levels induced via the transfection of mimics sig-
niﬁcantly depressed both ﬁreﬂy and Renilla luciferase
activity. Next we contrived SHSY5Y stable transfect-
ants of the engineered constructs. The established stable
transfectants responded well to both miR-182 or miR-
183 mimics (i.e. the transfection of these mimics caused
the depression of both ﬁreﬂy and Renilla luciferase aci-
tivities in each cell line (Supplementary Figure 2b)). Of
note, the endogenous levels of both miR-182 and miR-
183 are quite low in SHSY5Y cells and thus the basal
levels of luciferase activities are quite high
(Supplementary Figure 2a and b). In order to maintain
minimal basal levels of luciferase activities, we trans-
duced these stable cell lines with lentiviral particles con-
taining miR-182 (or miR-183) shMIMIC microRNAs
(Thermo Fisher Scientiﬁc), and in so doing established
Figure 1. Generation of dual-luciferase miRNA target expression constructs and their stable transfectants. (a) Commercially
available original vectors, pmirGLO and psiCHECK-1, which were designed to quantitatively evaluate miRNA activity via the insertion
of miRNA target sites on the 30 UTR of the firefly gene (luc2) (pmirGLO) or 30 UTR of the Renilla gene (hRluc) (psiCHECK-1). (b)
Insertion of annealed oligonucleotide pairs, which contain the miR-182 (or miR-183) target sequence with appropriate restriction sites
(PmeI and XbaI for pmirGLO, SgfI and PmeI for psiCHECK-1) downstream of luc2 in the pmirGLO and downstream of hRluc in the
psiCHECK-1. These vectors were digested with KpnI and BamHI and the fragments which contained the reporter units were isolated/
ligated. (c) The final construct consists of a dual reporter system utilizing both firefly and Renilla luciferase. (d) (1) Using SHSY5Y cells,
stable transfectants of the engineered reporter constructs were created (specific for either miR-182 [represented] or miR-183). (2) In
order to maintain minimal basal levels of activity of both luciferases, the stable host cells were transduced with lentiviral particles
containing miR-182 (or miR-183) shMIMIC microRNAs. (3) These stable transfectants (miR-182 or miR-183 target sequence in
pmirGLO/psiCHECK1 plus lentiviral particles containing miR-182 or miR-183 shMIMIC) were usable for high-throughput screens. The
final stable reporter cell line was designed to identify small compounds (e.g. HDAC inhibitor Panobinostat) that inhibit miR-182 (and/
or miR-183) generation or function, thereby resulting in the activation of the luciferases (both firefly and Renilla).
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cell lines that constitutively expressed these miRNAs
via the selective pressure of puromycin. We then exam-
ined whether these stable transfectants (miR-182 or
miR-183 target sequence in pmirGLO/psiCHECK1
plus lentiviral particles containing miR-182 or miR-183
shMIMIC) were usable for high-throughput screens. The
ﬁnal stable reporter cell line was designed to identify
small compounds that inhibit miR-182 (and/or miR-
183) generation or function, thereby resulting in the acti-
vation of the luciferases (both ﬁreﬂy and Renilla). We
used a miR-182 (or miR-183) inhibitor (miRIDIAN
microRNA hairpin inhibitor, Thermo Fisher Scientiﬁc)
as a positive control and non-speciﬁc miRNA
(miRIDIAN microRNA Negative Control, Thermo
Fisher Scientiﬁc) as a negative control. As shown in
Supplementary Figure 2(c), the basal level of luciferase
activities (both ﬁreﬂy and Renilla) are very low in com-
parison to negative controls in Supplementary Figure
2(a) and (b) and the activation by the miR-182 (or
miR-183) inhibitors were substantial. Calculated Z-fac-
tors, which represent a well-established quantitative
measure of the quality of an assay, were 0.61 for miR-
182/ﬁreﬂy, 0.5 for miR-182/Renilla, 0.47 for miR-183/
ﬁreﬂy, and 0.66 for miR-183/Renilla. Being that a Z-
factor between 0.5 and 1.0 corresponds to an excellent
assay, our assay system qualiﬁes as having suﬃcient sen-
sitivity for high-throughput screening.
Cell culture and transfection/transduction
The human neuroblastoma cell line SHSY5Y (ATCC
(Manassas, VA, USA)) and its stable derivatives (stable
reporter cell lines) were cultured in DMEM supple-
mented with 10% FBS, 100 U/mL penicillin and
100 mg/mL streptomycin (pen/strep) at 37C with 5%
CO2. Cortical neurons were isolated from E18 embryos
of Sprague-Dawley rats in accordance with the policies
set forth by the ACUC (Animal Care and Use
Committee) of NINDS and experiments were performed
according to ACUC, NIH, and ARRIVE guidelines
(http://www.nc3rs.org/ARRIVE). Cells were plated
on poly-L-lysine coated plates and cultured in
Neurobasal media (Gibco (Waltham, MA, USA)) sup-
plemented with B27 (Gibco), pen/strep as previously
described9; cells were used after seven days in culture.
Transfection of SHSY5Y cells was performed using
electroporation with nucleofector (Amaxa (Basel,
Switzerland)) for plasmid constructs and
Lipofectamine 2000 (Invitrogen (Waltham, MA,
USA)) for miR mimics or inhibitors per the manufac-
turers’ instructions. Transductions of shMIMIC
Lentiviral miRNA particles were performed at low mul-
tiplicities of infection (MOI) (i.e. 0.3) according to the
manufacturer’s (Thermo Fisher Scientiﬁc) instructions
in the media devoid of serum and antibiotics.
Assay for firefly and Renilla luciferase activities
We used ‘Dual-Glo Luciferase Assay System
(Promega)’ to measure luciferase (ﬁreﬂy and Renilla)
activities according to the manufacturer’s instructions.
Brieﬂy, after cells were transfected with the miRNA
mimics/inhibitors or treated with small molecules,
Dual-Glo Luciferase Assay reagent was added to each
well at a volume equal to that of the culture (i.e. 80 ml in
96-well plate; 4 ml in 1536-well plate), incubated for
10min at room temperature and the luminescence mea-
sured (ﬁreﬂy). Then, the Dual-Glo Stop and Glo
reagent was added to the plate (same volume as the
ﬁrst reagent), incubated for another 10min at room
temperature, and the luminescence measured
(Renilla). Luminescence in 96-well plates was measured
using a LB 960 Centro (Berthold Technology (Oak
Ridge, TN, USA)), while luminescence in 1536 plates
was measured via the ViewLux plate reader
(PerkinElmer (Waltham, MA, USA)).
qHTS assay and viability
For each cell line tested, a total of 2000 cells per well in
4 mL of media were dispensed using a Multidrop Combi
dispenser (Thermo Fisher Scientiﬁc) and a small cas-
sette into barcoded 1536-well ﬂat-bottom white
(Corning (Corning, NY, USA)) collagen-coated
plates. After a 24 h incubation, library compounds
and controls were added to assay plates at a volume
of 23 nL/well via a NX-TR pintool station (Wako
Scientiﬁc Solutions (San Diego, CA, USA)), and the
plates were incubated further (another 24 h). Fireﬂy
and Renilla luminescence outputs were measured
sequentially using the Dual-Glo Luciferase Assay
System (Promega) and the ViewLux plate reader
(PerkinElmer). The assay’s performance was stable
throughout the screen. The activity of each compound
was normalized to control wells (DMSO alone), which
were included on each plate. Cells treated with DMSO
alone were deﬁned as having 0% activity. Of note, the
following libraries were screened: the library of
pharmacologically active compounds (LOPAC),13
MIPE14 and the NIH Chemical Genomics Center
(NCGC) Pharmaceutical Collection (NPC).15
Western blot analysis
Whole cell lysates were prepared and subjected to SDS-
PAGE as described previously.9 The antibodies used in
this study were: anti-SUMO-1 (rabbit polyclonal, in
house), ant-SUMO-2,3 (rabbit polyclonal, in house),
anti-Ubc9 (rabbit monoclonal, Abcam (Cambridge,
UK)) and anti-b-actin (mouse monoclonal, Sigma (St.
Louis, MO, USA)). Intensities of bands were analysed
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using Image-J (NIH (Bethesda, MD, USA)). In order
to measure SUMO conjugation levels, the region cor-
responding to molecular weights above 100 kDa in each
lane was cropped and the total intensity was analysed.
The densities were normalized with corresponding actin
levels and expressed as the ratio to control (DMSO
alone).
OGD and the assessment of cell death
OGD for SHSY5Y and rat cortical neurons were
performed as described previously.6,9 We subjected
cells with or without drugs to OGD for 15 h
(SHSY5Y cells) or 5 h (cortical neurons) followed by
the restoration of oxygen/glucose (ROG) for 6 h
(SHSY5Y) or 16 h (cortical neurons). The duration of
OGD and ROG was determined by our previous stu-
dies.6,9 Cell death was assessed via nuclear staining with
Hoechst 33342 and propidium iodide (PI) followed by
ﬂuorescence-activated cell sorting (FACS) analysis.6,9
Typically, 1 105 cells were analysed. The percentage
of total cell death (both apoptotic and necrotic) was
calculated by taking the diﬀerence of viable cell popu-
lations between non-OGD and OGD-subjected, and
dividing it by the viable cell population of non-OGD,
with the understanding that some of compounds them-
selves may have an eﬀect on cell viability without OGD
(i.e. toxicity at time points> 13 h). The compounds
were all dissolved in DMSO and were subsequently
diluted to attain a ﬁnal DMSO concentration of 0.1%
in all experiments, and 0.1% DMSO alone, without
drug was used as our OGD/ROG control. We normal-
ized the calculated cell deaths to the 0.1% DMSO con-
trol within each experiment. Cell death was also
assessed by measuring LDH release according to the
manufacturer’s directions (Abcam).
Quantification of neuronal apoptosis/death via
microscopic histology
Primary cortical neurons were plated at a density of
3 105 on poly-L-lysine-coated Lab-Tek chamber
slides (Nalge Nunc International (Waltham, MA,
USA)) for the assessment of neuronal apoptosis/
death. After OGD or OGD/ROG, neurons were
ﬁxed/subsequently stained with terminal deoxy-nucleo-
tide transferase dUTP nick end labeling (TUNEL) and
a rabbit anti-b-tubulin (Covance (Princeton, NJ, USA)
MRB-435 P) antibody, followed by an
anti-rabbit Alexa Fluor 647-conjugated secondary anti-
body. Nuclei were counterstained with 40,6-diamidino-
2-phenylindole (DAPI). Brieﬂy, for TUNEL staining
(APO-BrdUTM TUNEL Assay, Thermo Fisher
Scientiﬁc), 70% ethanol-ﬁxed cells were incubated in
the provided DNA-labelling solution which contained
TdT and BrdUTP for 1 h at 37C. After incubating the
cells with the staining solution (Alexa Fluor 488 dye-
labeled anti-BrdU antibody) for 30min at RT, the PI/
RNase A staining buﬀer was applied for an additional
30min. TUNELþ cells were then manually counted
using microphotographs collected at six random
regions of interest (ROIs). Data are expressed as
mean percentage standard error (SE) of TUNELþ
cells over DAPI.
Analysis of dendritic arborizations and spines
Primary cortical neurons were plated at a density of
1.5 105 cells in chamber slides for the assessment of
dendritic arborizations and spine density. After OGD
or OGD/ROG, neurons were ﬁxed/stained using a
chicken anti-microtubule-associated protein 2
(MAP2) (Abcam ab5392) and a mouse anti-postsynap-
tic density protein 95 (PSD95) (Abcam ab2723) pri-
mary antibodies, followed by an anti-chicken Alexa
Fluor 488-conjugated and an anti-mouse Alexa Fluor
568-conjugated secondary antibody respectively.
Nuclei were counterstained with DAPI. For the initial
assessment of MAP2 immunoreactivity, immunoﬂuor-
escence stainings were evaluated using a CCD camera/
ﬂuorescence microscope; n¼ 6 equally distributed
ROIs were acquired via a 20x objective lens for ana-
lysis. Data are expressed as MAP2þ area (mm2)  SE
over DAPI. MAP2þ/PSD95þ neurons were then ana-
lysed in more detail using a 63x objective lens for the
evaluation of dendritic arborizations and spines.
Criteria for inclusion within the analyses were the fol-
lowing: (i) the neuron had to be well stained; (ii) the
neuron had to be in full view, (i.e. neither obscured/
obstructed by overlapping dendrites from other neu-
rons); and (iii) the neuron had to contain intact den-
dritic arborizations (i.e. not display any obvious signs
of degeneration).16 The ﬁrst four neurons from
each experimental condition that ﬁt the abovemen-
tioned criteria were reconstructed by following the
dendrites through the z-axis, and the length of each
dendritic branch was determined using Sholl and
Branch analysis via StereoInvestigator software
(MicroBrightField (Williston, VT, USA)), as has
been previously described.17 For statistical analysis,
we used a standard software package (GraphPad
Prism version 4.0). Histological data were evaluated
by unpaired two-tailed t-tests (for comparisons
between two groups) and by one-way ANOVA fol-
lowed by Newman–Keuls tests for post hoc analysis
(for comparison amongst  three groups). To test for
diﬀerences in dendritic length (Sholl analysis), a two-
way ANOVA, followed by Tukey’s post hoc test, was
performed. Values of p 0.05 were deemed to be
signiﬁcant.
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Active compound-gene (protein) interaction and
stroke enrichment enquiry
The Ingenuity Pathway Analysis (IPA) tool was used
(www.ingenuity.com). Compounds by name were
entered into IPA and all known gene (protein) inter-
actions supported by IPA returned. These interactions
were summarized in IPA via a network view and enum-
erated/compared across compounds via a bar plot
using Microsoft Excel. IPA was also used to identify
biological pathways and functions enriched with pro-
teins having interactions with each compound, by com-
pound. Enrichment results were summarized both by
heat map using R (www.cran.r-project.org) and by
bar plot using Microsoft Excel. Lastly, IPA was queried
for all proteins having association with stroke. These
stroke-associated proteins were then intersected with
proteins having interaction with each compound by
compound and an enrichment p-value calculated for
the intersection via Chi-square test with Yates correc-
tion using GraphPad Prism.
qHTS data analysis
Plate-based qHTS data were normalized and concen-
tration–eﬀect relationships derived using in-house
developed software.18 The activity of each compound
was normalized to vehicle control wells (DMSO), which
were included on each plate, and reported as an abso-
lute percentage change in signal relative to these control
wells. EC50 values were obtained by data ﬁt using a
residual error minimization algorithm with automatic
outlier determination to a four-parameter Hill equation
as the dose–response model. Concentration–eﬀect rela-
tionships (CERs) were categorized by ﬁt quality (r2),
response magnitude, and degree of measured activity.18
Results
Quantitative high-throughput screening (qHTS) via
a dual luciferase reporter assay for the identification
of inhibitors of miRNA 182/183
The ultimate goal of this work was to develop a system
capable of identifying molecular entities (MEs)/active
pharmaceutical ingredients (APIs) capable of upregulat-
ing global SUMOylation through the inhibition of
miRNAs 182 and/or 183. To minimize interference and
increase our conﬁdence in hits ascertained during screen-
ing, we designed constructs that contain two diﬀerent
reporters (dual reporter system), ﬁreﬂy luciferase and
Renilla luciferase (Figure 1), which are not homologous
and therefore have unrelated bioluminescent properties.
We conﬁrmed that the presence of mature miR-182 or
miR-183 would lead to a decrease in luciferase (both
ﬁreﬂy and Renilla) signal, enabling the detection of puta-
tive miR-182 (or miR-183) levels (Supplementary Figure
2). We then established cell lines which stably expressed
these constructs as described in Figure 1, and used them
for the screening of small molecule libraries in a 1536 well
format. From a total of 4489 compounds screened, 120
compounds were initially identiﬁed in the course of the
primary screening process. These 120 compounds were
subsequently selected and re-screened for validation
through the use of conﬁrmatory assays. From the
follow-up screening, 21 active compounds (listed in
Table 1) were conﬁrmed based on their activities in
both ﬁreﬂy and Renilla luminescence assays and were
taken forward for further study/characterization. We
note that most conﬁrmed compounds do not give equiva-
lent percentage changes in signal in both channels, per-
haps due to a diﬀerence in sensitivity in the detection
methodology for these readouts (Figure 2 and
Supplementary Figure 3).
Active compounds identified during the primary
screen induced SUMO conjugation in SHSY5Y cells
and rat E18 primary cortical neurons
To determine the eﬀect of the active compounds identi-
ﬁed via the primary screen on the induction of SUMO
Table 1. Molecular entities – libraries of origin and regulatory
status.
Molecular entity Library Status
1 Romidepsin NPC Approved drug
2 Panobinostat NPC Clinical testing
3 Entinostat NPC Clinical testing
4 Belinostat NPC Approved drug
5 Pracinostat NPC Approved drug
6 Fosmidomycin NPC Clinical testing
7 NCGC00185916 NPC Preclinical testing
8 Licofelone NPC Clinical testing
9 Motesanib NPC Clinical testing
10 Orotic acid NPC Clinical testing
11 JWH-015 LOPAC Preclinical testing
12 5-Azacitidine LOPAC Approved drug
13 AHPN NPC Preclinical testing
14 Lenalidomide NPC Approved drug
15 Vatalanib NPC Clinical testing
16 VX-702;KVK-702 NPC Clinical testing
17 Dianiline NPC Preclinical testing
18 Diazoxide NPC Approved drug
19 Telmisartan NPC Approved drug
20 JQ1 NPC Preclinical testing
21 TW-37 NPC Preclinical testing
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conjugation, the 21 compounds were tested in orthogonal
cell-based assays with SHSY5Y cells. The compounds
were incubated with SHSY5Y cells for 13.5 h at both a
low and high concentration extrapolated from the con-
centration–response curves of the conﬁrmatory assay. As
shown in Figure 3, immunoblotting eﬀectively demon-
strated that the majority of the compounds identiﬁed
were indeed capable of upregulating SUMO1 and
SUMO-2/3 conjugation, thereby conﬁrming the biologic
validity of the positive hits resulting from the qHTS
assay. Further, it was noted that many of the compounds
seemed to increase the levels of the sole SUMO E2 con-
jugase Ubc9 as well (Figure 3). To examine whether the
upregulation of global SUMO conjugation by these com-
pounds in SHSY5Y cells (stable derivatives of which we
used for the screening) were cell type speciﬁc, or not, we
next examined the eﬀect of the compounds on the
SUMOylation levels of primary cortical neurons isolated
from rat embryos. Since the lower dose of the majority of
the compounds had a similar eﬀect when compared to
the higher dose in SHSY5Y cells (Figure 3), we explored
the lower/physiologically compatible dose in primary
cortical neurons. As shown in Figure 4, most compounds
were capable of increasing the levels of global SUMO
conjugation in primary cortical neurons. Interestingly,
the levels of global SUMOylation induced did vary
from compound to compound between the SHSY5Y
cell line and the primary cortical neurons (Figures 3
and 4). To exclude the confounding contributions of
compound cytotoxicity, a cell viability assay was per-
formed in parallel with the SUMO conjugation assay.
We found that the increases in global SUMOylation
were unrelated to a cellular stress response or cell death
as compound cytotoxicity was not observed; critically,
cells were treated with the compounds for an equivalent
amount of time (Supplementary Figure 4).
qHTS identified active compounds are capable
of inducing protection against oxygen/glucose
deprivation (OGD)/restoration of oxygen/glucose
(ROG)
The ultimate goal of this qHTS was to characterize a
novel method capable of uncovering small molecules
that might be used for the treatment of ischemic
stroke. The 21 compounds were consequently tested
for their putative eﬃcacy in protecting SHSY5Y cells
from OGD followed by ROG in vitro. Concentrations
were chosen based on the aforementioned qHTS
(Supplementary Table 1). As shown in Figure 5(a),
most compounds induced protection from OGD/ROG-
induced cell death in SHSY5Y cells, with Panobinostat
(a histone deacetylase [HDAC] inhibitor) and 6-[3-ada-
mantyl-4-hydroxyphenyl]-2-napthalene carboxylic acid
(AHPN), a synthetic retinoid, being the most eﬀective.
We then tested the active compounds that displayed stat-
istically signiﬁcant eﬀects in E18 primary cortical neu-
rons. We found that far fewer compounds displayed
protective eﬀects against OGD/ROG in E18 primary
cortical neurons as compared to SHSY5Y cells, but
again AHPN was noted to be eﬀective (Figure 5b).
Being that AHPN was found to be the most eﬀective
compound in protecting both SHSY5Y and E18 primary
cortical neurons from OGD/ROG-induced cell death,
we decided to further characterize its eﬀects on primary
Figure 2. Dose–response curves. (a) The non-specific
response of Dianiline across five concentrations. (b) The miRNA-
182 specific response of Panobinostat. (c) The miRNA-183 spe-
cific response of AHPN.
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Figure 3. Treatments with small molecules identified by qHTS increase the levels of SUMO conjugation and the Ubc9 conjugase in
SHSY5Y parent cells. (a) Representative immunoblots of high molecular weight (>100 kDa) SUMO-1 and SUMO-2,3 conjugates and
the Ubc9 protein in the total cell lysates from SHSY5Y cells treated with various compounds with indicated concentrations for 13.5 h.
(b) Quantitative analyses of the conjugates and Ubc9 from three independent experiments. High molecular weight SUMO-1 or
SUMO-2,3 conjugates (>100 kDa) were cropped in each lane and the total intensity measured. The densities were normalized to
corresponding actin levels and expressed as the ratio to control (DMSO alone). Data represent the mean+/standard deviation of
three independent experiments. **p< 0.01, *p< 0.05 compared to DMSO control.
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cortical neurons. As previously reported, OGD/ROG
treatment causes both apoptosis/necrosis and these
populations can be distinguished via FACS.9 As shown
in Figure 5(c), 5 h OGD followed by 16h ROG caused
40% cell death (30% apoptosis/10% necrosis) in
untreated cells (i.e. DMSO alone) whilst increasing con-
centrations of AHPN during OGD/ROG provided
statistically signiﬁcant decreases in amounts of cell
death. While both apoptosis and necrosis levels were
decreased, AHPN was most eﬀective in decreasing the
number of apoptotic cells. Total cell death after OGD/
ROG was also assessed by LDH release (Figure 5d). In
addition, we analysed how AHPN protects primary cor-
tical neurons after 5 h OGD, or 5h OGD followed by
Figure 4. The effect of small molecules identified by qHTS on SUMO conjugation and Ubc9 levels in E18 rat cortical neurons.
(a) Representative immunoblots of high molecular weight (>100 kDa) SUMO-1 and SUMO-2,3 conjugates and the Ubc9 conjugase in
the total cell lysates from rat E18 primary cortical neurons treated with various compounds with the indicated concentrations for
13.5 h. (b) Quantitative analyses of the conjugates and Ubc9 from three independent experiments. Data represent the mean+/
standard deviation of three independent experiments. **p< 0.01, *p< 0.05 compared to DMSO control.
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16h ROG via both TUNEL and MAP2/PSD95 stain-
ing. We found that 1mM AHPN induced a signiﬁcant
reduction in TUNELþ neurons (a marker of cell apop-
tosis/death) when compared with both control neurons
exposed to OGD and OGD/ROG (Figure 6a).
Interestingly, the lowest dose of AHPN (0.2mM) also
displayed a signiﬁcant eﬀect on the survival of OGD/
ROG neurons (Figure 6a). Critically, both in vivo ische-
mia and in vitro OGD have been shown to induce alter-
ations of dendrites (i.e. early degeneration19 and a
compensatory outgrowth20). As such, we decided to
examine MAP2 immunoreactivity in the surviving cor-
tical neurons after OGD and OGD/ROG, being that
MAP2 is a cytoskeletal phosphoprotein that provides
scaﬀolding within dendrites, particularly near spines.19
Interestingly, we found that AHPN was capable of pre-
venting a decrease in MAP2 intensity after OGD and
OGD/ROG in a dose-dependent manner (Figure 6b).
We then examined the dendritic arborization of primary
cortical neurons and focused our attention on PSD 95
positive spines (Figure 6c and d). Sholl analysis per-
formed on the neuronal three-dimensional (3D) recon-
structions conﬁrmed that the total dendritic length was
diﬀerent among groups with a signiﬁcant decrease in
dendritic arborizations occurring after exposure to
OGD and OGD/ROG as compared to non-hypoxic con-
trols. Interestingly, AHPN at 1mM was capable of sig-
niﬁcantly inhibiting the decrease in neurons subjected to
OGD (Figure 6c) while it had no clear eﬀect on neurons
exposed to both OGD/ROG (Figure 6d).
Gene/protein expression and biological pathways
perturbed by active compounds
To explore the potential mechanisms of the active
compounds, the Ingenuity Pathway Analysis (IPA)
knowledgebase was used to query all gene (protein)
interactions contained therein having association
with the compounds listed in Figure 7.
Summarization and exploration of these interactions
via a network diagram revealed that certain com-
pounds have a greater number of interactions than
others; suggesting the perturbation potential at the
molecular level for these compounds may too be
Figure 5. The effect of small molecules identified by qHTS on
OGD/ROG-induced cell death in SHSY5Y cells and E18 rat
cortical neurons. After OGD/ROG exposure (OGD/ROG: 16 h/
5 h for SHSY5Y, 5 h/16 h for cortical neurons) in the presence or
absence of the small molecules indicated, cell death/survival was
assessed via nuclear staining with Hoechst 33342 and propidium
iodide (PI) followed by FACS analyses. The percentage of total
cell death (both apoptotic and necrotic) was calculated and
recorded vs the percentage of 0.1% DMSO control cell death in
each experiment. (a) SHSY5Y cells. (b) Rat cortical neurons.
(c) Increasing concentrations of AHPN displayed statistically
significant increases in viability and decreases in cell death after
OGD/ROG as measured by FACS analysis. Upper panels: rep-
resentative dot plots without AHPN (left) and with 1mM AHPN
(right) with numbers in each population (left, apoptotic cells;
upper right, necrotic cells; lower right, viable cells); lower panels:
Quantitative analyses of cell survival (left) and cell death (right).
(d) Increasing concentrations of AHPN displayed statistically
significant decreases in cell death as measured by LDH release.
Data represent the means standard deviation of three inde-
pendent experiments. **p< 0.01, *p< 0.05 compared with
OGD/ROG without AHPN by student’s t-test.
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greater. To enumerate and compare the diﬀerence in
number of interactions across compounds, a bar plot
was constructed. By this plot, AHPN has the greatest
number of interactions compared to licofelone, a dual
COX/LOX inhibitor, which has the fewest. To further
elucidate a compound’s perturbation potential at the
molecular level, IPA was used again to identify those
biological pathways and functions supported in IPA
that are signiﬁcantly enriched (Fisher’s exact test
p< 0.05) for the genes (proteins) associated with
each compound. To enumerate and compare the dif-
ference in number of signiﬁcantly enriched biological
pathways and functions across compounds, bar plots
were constructed. From these plots, compounds
having the greatest number of signiﬁcantly enriched
biological pathways (e.g. AHPN, romidepsin, and
entinostat) and functions (e.g. romidepsin, entinostat,
and telmisartan) could be readily identiﬁed and argued
to have the greatest perturbation potential at the bio-
logical pathway and function levels. Of particular
interest is Supplementary Table 2, which describes the
number of associated genes (proteins) per compound in
IPA, the number of genes (proteins) associated with
stroke in IPA, and whether the intersection via Chi-
square test is signiﬁcant (Yates corrected p< 0.05) or
not. Per the results, 64% of the active compounds (9/
14) were found to be signiﬁcantly enriched for genes
(proteins) associated with stroke.
Figure 6. AHPN reduces ischemic neuronal apoptosis and preserves dendritic/synaptic integrity in vitro. (a) Representative images of
TUNELþ (in green) and b-tubulinþ (in red) neurons and quantitative analysis. Nuclei are counterstained with DAPI (blue). Scale bars:
100 mm. Data are means standard error. *p 0.05, compared with OGD and OGD/ROG controls, respectively. þþþp 0.001,
þþp 0.01, compared with non-hypoxic CTRL neurons; **p 0.01, *p 0.05, compared with OGD or OGD/ROG controls. (b)
Representative microphotographs of primary cortical neurons dendrites stained for MAP2 (green) and corresponding quantification.
Nuclei are counterstained with DAPI (blue). Scale bars: 100mm. Note the dose-dependent increase of MAP2 expression induced by
AHPN in both OGD and OGD/ROG treated neurons. þþp 0.01 compared with non-hypoxic CTRL neurons; *p 0.05, compared
with OGD or OGD/ROG controls. (c,d) Representative reconstructions and microphotographs of OGD (c) and OGD/ROG (d)
primary cortical neurons treated with AHPN. Dendrites are stained with MAP2 (green), while spines are stained with PSD95 (red).
Nuclei are counterstained with DAPI (blue). Scale bars: 10 mm. Sholl analysis of dendritic length with nested concentric spheres
centred at the cell soma and with a gradually increasing radius (5 mm) showing cumulative dendritic length in the function of cell soma
distance, the integrated total dendritic length, and the spine density of primary cortical neurons. þp 0.05, compared with non-
hypoxic CTRL neurons, **p 0.01, *p 0.05, compared with OGD or OGD/ROG controls.
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Discussion
Therapeutic options for ischemic brain injury are lim-
ited. As such, the research presented herein seeks to high-
light the development of a novel cell-based qHTS system
designed to streamline the clinical development and
translation of previously approved drugs that may ultim-
ately be repurposed for the treatment of ischemic stroke.
In an eﬀort to elucidate targets capable of providing the
plurifunctional cytoprotection needed to overcome the
inherent complexities of stroke pathobiology, mechan-
isms of tolerance were examined in the hibernating 13-
lined ground squirrel. I. tridecemlineatus has an extraor-
dinary capacity to withstand prolonged and profound
reductions of blood ﬂow and oxygen delivery to brain
without incurring any cellular damage.7 One of the
underlying molecular means allowing this multifactorial
cytoprotection to unfold is that of global
SUMOylation.6,9 The identiﬁcation of miRNAs 182
and 183 (reported functions reviewed by Lee et al.12)
as an endogenous mechanism, which in part controls
global SUMOylation, pushed us to identify small mol-
ecules capable of regulating this form of post-transla-
tional modiﬁcation via miRNA as novel targets for
development of stroke therapies.12
MicroRNAs are key players within gene regulatory
networks and modulate multimodal gene expression by
binding to complementary sequences in target mRNAs,
and as such are critically positioned to inﬂuence net-
work dynamics/outcomes. One miRNA usually targets
more than one hundred genes21 with interactome hubs
Figure 7. Off-target enquiry. The Ingenuity Pathway Analysis tool (IPA) was used to query all gene (protein) interactions by com-
pound (www.ingenuity.com). These interactions were summarized in two ways. First, a network was constructed across compounds
to demonstrate that no exclusive gene (protein) interactions exist (upper left plot). Second, a bar plot was constructed to describe
that the number of gene (protein) interactions by compound is unbalanced (lower left plot). To gauge and compare compound impact
on biological pathways and functions, IPA was used to report enrichment p-values (Fisher’s exact test) for 562 pathways (upper right
plot) and 3455 functions (lower right plot).
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and downstream signaling components (e.g. transcrip-
tion factors) typically regulated by more miRNAs than
other nodes within a given network.22,23 Of note,
miRNA binding may suspend and/or permanently
repress the translation of a given mRNA transcript,24,25
thereby altering post-transcriptional gene proﬁles.
Drugs that directlymodulate a singlemolecular target
have come to be understood as insuﬃcient for the cyto-
protective treatment of ischemic stroke, unless such a
target is itself critically positioned to inﬂuence a net-
work.22 If one seeks to combat the pathobiology under-
lying complex and/or polygenic disease processes, the
design of a new generation of eﬃcacious drugs must be
developed tomodulate diseased cellular networks.22,26,27
Accordingly, the rationale for polypharmacology (i.e.
the promiscuous modulation of several molecular tar-
gets simultaneously)26 has progressively garnered sup-
port in both academia and industry. Understanding
the plurifunctional underpinnings of miRNA and its
relationship to global SUMOylation, we sought to
develop a screening system capable of identifying MEs
capable of inﬂuencing post-ischemic clinical outcomes.
Acknowledging that luciferase-dependent assay inter-
ference in qHTS cannot be entirely eliminated, it is none-
theless possible to signiﬁcantly reduce the probability of
its occurrence through the rational engineering of one’s
reporter system and via the selection of appropriate
orthogonal assays to conﬁrm compound activity. Both
of the aforementioned represent the best means of iden-
tifying artifactual activity early in drug discovery pro-
cesses.28 Further, many of the compounds within
screening libraries directly perturb the activity of lucifer-
ase reporters, thus skewing data interpretation and com-
plicating candidate selection.28–31 In order to facilitate
the construction of a functional cell-based qHTS assay
capable of accurately identifying inhibitors of our
miRNAs of interest, we constructed stable dual ﬁreﬂy-
Renilla luciferase reporter lines, thereby reducing the
number of downstream manipulations and enhancing
concurrently the overall reproducibility of the assay.
To minimize interference and increase our conﬁdence
in hits during screening, we designed a construct that
contains two diﬀerent reporters. Of note, ﬁreﬂy lucifer-
ase and Renilla luciferase are not homologous and
therefore have unrelated bioluminescent properties; ﬁre-
ﬂy luciferase uses d-luciferin as its substrate, while
Renilla luciferase makes use of coelenterazine as its sub-
strate.32 Our assay rules out false-positives due to com-
pound toxicity, which can occur in an assay based on a
decrease in reporter signal. Moreover, since compounds
identiﬁed using this proprietary screening approach
may still have oﬀ-target eﬀects, they need to be vali-
dated using orthogonal assays following the primary
assay to diﬀerentiate between compounds that generate
false positives verse those compounds that are
speciﬁcally active against the target. As such, we con-
ﬁrmed our screening with a series of western blots and in
so doing demonstrated the overall reliability of our
assay.
The ﬁnal strength of this novel dual reporter assay
system is its downstream utility in exploring the drug-
ability of other miRNAs of clinical interest in a qHTS
manner (i.e. via the insertion of the appropriate target
sequences into the pmirGLO/psiCHECK1 ﬁreﬂy and
Renilla 30 UTRs) expanding upon the elegant technique
originally put forth by Connelly et al.33
Of the 21 compounds that deﬁnitively emerged from
the screen and the following orthogonal assay, we
noted that ﬁve were HDAC inhibitors: romidepsin,
panobinostat, entinostat, belinostat, and pracinostat.
HDAC inhibitors are a class of drugs that increase
the acetylation of histone and non-histone proteins to
activate transcription, enhance gene expression, and
modify the function of target proteins.34 HDAC inhibi-
tors have been shown in a myriad of basic and preclin-
ical studies to provide vigorous protection against
excitotoxicity, oxidative and endoplasmic reticulum
stress, apoptosis, inﬂammation, and blood brain barrier
breakdown, all of which are core components of the
pathobiology caused by an acute ischemic brain insult
(reviewed in Fessler et al.34). Beyond the suppression of
post-stroke injury, HDAC inhibitors have been shown
capable of augmenting recovery through the promotion
of angiogenesis, neurogenesis, and stem cell migration,
thereby dramatically increasing both functional and
behavioral recovery after experimental cerebral ische-
mia.34 Intriguingly, work has emerged to link HDAC
inhibitors to the regulation of miRNA in ischemia35
and cancer models.36,37 Of particular interest,
Blakeslee et al. have provided a direct link between
HDAC inhibition and SUMOylation in both cardio-
myocytes and ﬁbroblasts that may help explain the
beneﬁcial eﬀects of HDAC inhibitors in preclinical
models of heart failure.38 Of note, the protective inﬂu-
ences of the HDAC inhibitors have a foil in the class’
baseline toxicity, and it has therefore proven diﬃcult to
optimize the concentrations that may ultimately
achieve maximal protection from OGD/ROG.39
Strategies including pulsed treatment may be employed
to mitigate such toxicity moving forward.40
The compound that had the most pronounced eﬀect
in both cell lines (SHSY5Y and cortical neurons) was
AHPN. Disruption of retinoid signaling has been linked
to the pathological hallmarks of a number of neuroin-
ﬂammatory/neurodegenerative diseases that share com-
ponents of ischemic pathobiology.41,42 As such, both
endogenous and synthetic retinoids (AHPN) have been
examined for their ability to modulate inﬂammation via
interactions with both macrophages and micro-
glia.41,43,44 Previous reports have documented AHPN’s
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ability to act as a chemotherapeutic via an inhibition of
cellular proliferation and/or induction of apoptotic cell
death.45,46 Despite this, the work by Farso et al. has
eﬀectively demonstrated AHPN’s ability, at low concen-
trations, to attenuate microglial activation-associated
responses without triggering cell death.41 Such work
highlights the critical nature of AHPN dose to related
biological outcomes and suggests that more work will be
needed to fully elucidate this molecule’s protective cap-
acity. It is again prudent to note that a number of the
other compounds which proved capable of providing
protection against the injurious eﬀects of OGD/ROG
in the primary cortical neurons have been linked previ-
ously with neuroprotection after ischemia; accordingly,
orotic acid, diazoxide and telmisartan have all been
shown capable of modulating relevant components of
ischemic pathobiology.47–49
Of interest, the response of both cell types (SHSY5Y
and cortical neurons) to the drugs diﬀered and the level
of protection induced did not directly correlate with the
level of global SUMOylation, as may have been
expected. We therefore propose that the SUMOylation
of speciﬁc target sets may be a critical component of the
protection aﬀorded against ischemia in addition to
global SUMOylation levels as evidenced by the recent
work of Yang et al.50 Such diﬀerences may ultimately be
exploited to further elucidate the dynamics controlling
both global SUMOylation and its inﬂuence on neuro-
protection during OGD/ROG.
Understanding both the burden of disease caused by
ischemic stroke and our concurrent lack of cell protect-
ive therapeutic options, we sought to engineer and opti-
mize a novel mechanism to identify molecules capable
of inducing global SUMOylation via the inhibition of
miRNA. Such work has considerable potential, and it is
our hope that it will lead to advanced therapies that
may be used to signiﬁcantly reduce morbidity/mortality
following ischemic brain injury, thereby improving
quality of life for both patients and their families.
Future work will seek to optimize doses (of single
drugs and combinations) both in vitro and ultimately
in vivo to further explore the potential clinical transla-
tion of our ﬁndings.
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